Advertisement

Pathological Complete Response (PCR) with TDM1 (Trastuzumab Emtansine) in Refractory HER2-Positive Locally Advanced Breast Cancer (LABC)

  • Manikandan DhanushkodiEmail author
  • Priya Iyer
  • Balasubramanian Ananthi
  • Arvind Krishnamurthy
Case report
  • 6 Downloads

Abstract

We report a patient with HER2-positive locally advanced breast cancer who progressed on neoadjuvant chemotherapy, chemoradiation and anti-HER2-based chemotherapy but achieved complete pathologic response with TDM1 (trastuzumab emtansine).

Keywords

TDM1 Pathologic complete response 

Notes

Compliance with Ethical Standards

Conflict of interest

Authors declare that they have no conflict of interest.

References

  1. 1.
    Gianni L, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Lond Engl. 2010;375:377–84.CrossRefGoogle Scholar
  2. 2.
    Gianni L, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32.CrossRefGoogle Scholar
  3. 3.
    de Azambuja E, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014;15:1137–46.CrossRefGoogle Scholar
  4. 4.
    Durkee BY, et al. Cost-effectiveness of Pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:902–9.CrossRefGoogle Scholar
  5. 5.
    Guiu S, Mouret Reynier MA, Toure M, Coudert B. Predictive factors of response in HER2-positive breast cancer treated by neoadjuvant therapy. J Oncol. 2013;2013:854121.  https://doi.org/10.1155/2013/854121.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Verma S, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91.CrossRefGoogle Scholar
  7. 7.
    Gullo G, et al. Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the ‘one thousand HER2 patients’ project. Br J Cancer. 2018;119:374–80.CrossRefGoogle Scholar

Copyright information

© Association of Gynecologic Oncologists of India 2019

Authors and Affiliations

  1. 1.Department of Medical OncologyCancer Institute (WIA)ChennaiIndia
  2. 2.Department of Radiation OncologyCancer Institute (WIA)ChennaiIndia
  3. 3.Department of Surgical OncologyCancer Institute (WIA)ChennaiIndia

Personalised recommendations